Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 3/20 | 0.51 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.44 |
| ▸ | PARP1 | P09874 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | PANK3 | Q9H999 | 6/20 | 0.40 |
| ▸ | SMO | Q99835 | 2/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | GPR39 | O43194 | 1/20 | 0.39 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.39 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14581838 | 0.96 | HSD11B1 (0.48) | HSD11B1GPR119PARP1HTTPANK3 | |
| SCHEMBL5481967 | 0.90 | HSD11B1 (0.51) | HSD11B1GPR119PARP1PANK3SMO | |
| SCHEMBL5466689 | 0.87 | HSD11B1 (0.48) | HSD11B1GPR119PARP1PANK3SMO | |
| SCHEMBL5466940 | 0.86 | PANK3 (0.40) | HSD11B1GPR119HTTPANK3SMO | |
| SCHEMBL5471745 | 0.85 | HSD11B1 (0.48) | HSD11B1PARP1PANK3 | |
| SCHEMBL14581794 | 0.85 | HSD11B1 (0.46) | HSD11B1GPR119PARP1SMOCHRM1 | |
| SCHEMBL5468420 | 0.85 | HSD11B1 (0.48) | HSD11B1GPR119PANK3SMOCHRM1 | |
| SCHEMBL5483019 | 0.84 | HSD11B1 (0.51) | HSD11B1GPR119PARP1PANK3SMO | |
| SCHEMBL14581841 | 0.83 | HSD11B1 (0.45) | HSD11B1GPR119PARP1PANK3SMO | |
| SCHEMBL5476228 | 0.81 | KDM4E (0.58) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070027118-A1 | Novel compounds of amino sulfonyl derivatives | AGOURON PHARMACEUTICALS, INC | 2007-02-01 | — | — | US | disclosed |
| US-20070027118-A1 | Novel compounds of amino sulfonyl derivatives | AGOURON PHARMACEUTICALS, INC | 2007-02-01 | — | — | US | disclosed |
| US-20070027118-A1 | Novel compounds of amino sulfonyl derivatives | AGOURON PHARMACEUTICALS, INC | 2007-02-01 | — | — | US | disclosed |
| WO-2006106423-A2 | AMINO SULFONYL DERIVATIVES AS INHIBITORS OF HUMAN 11-.BETA.-HYDROSYSTEROID DEHYDROGENASE | PFIZER INC. (US) | 2006-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027118-A1 | Novel compounds of amino sulfonyl derivatives | HSD11B1, HSD11B2, HSD17B11 | HSD11B1 1/4885GPR119 29/4885PARP1 4127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.